ScienceDaily (Dec. 26, 2005) — A third of patients treated for schizophrenia who stop taking their medication early do so because they do not feel any significant improvement or because their symptoms are worsening. A study published today in the open access journal BMC Medicine reveals that patients with schizophrenia are three times more likely to stop treatment because of poor response or worsening symptoms, than because of adverse non-psychiatric side effects.

Hong Liu-Seifert and colleagues from Eli Lilly and Company in Indianapolis, USA, analysed the reasons for stopping treatment of patients who took part in four previous Eli Lilly studies. The studies included a total of 1627 patients and compared the effects of taking olanzapine, risperidone, quetiapine or ziprasidone in patients diagnosed with schizophrenia or related disorders.

Liu-Seifert et al.'s analysis shows that 53% (866/1627) of patients stopped treatment early. Of the 866 patients who stopped treatment, 36% (315/866) did so because the treatment was felt not to be effective or because their symptoms worsened. Only 12% of patients who stopped treatment early did so because of adverse events such as dizziness, fatigue, vomiting or weight gain.

Of the 315 patients who stopped because of poor response to treatment, 80% stopped because they themselves believed it wasn't effective. Only 20% of the patients studied stopped taking medication based on a doctor's decision that the treatment wasn't effective.

"Discontinuation due to patient perception of poor response appeared to occur particularly early in the course of treatment," the authors write. Liu-Seifert et al. found that patients who experienced an early response to medication were 80% more likely to complete treatment.

The authors' findings suggest that early and effective symptom control, and discussing expectations of treatment, may help to ensure that people suffering from schizophrenia continue to take their medication.

Article:
Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs
Hong Liu-Seifert, David H Adams and Bruce J Kinon
BMC Medicine 2005, 3:21 (23 December 2005)

Email or share this story:  

Related Stories

Anti-Inflammatory Medications May Become A Treatment For Schizophrenia (Oct. 28, 2008) — Many of the structural and neurochemical features of schizophrenia are present long before the full syndrome of schizophrenia develops. What processes tip the balance between the ultra-high risk ...  > read more

Changes In Brain Density Can Help Predict Schizophrenia (Dec. 11, 2006) — Changes in brain density could be used to predict whether an individual who is at risk for schizophrenia is likely to develop the condition or not. A study published today in the open access journal ...  > read more

Schizophrenia Patients Who Are Likely To Receive Depot Medication Identified (Apr. 30, 2007) — A recent report has identified a unique subgroup of schizophrenia patients in the United States who tend to receive depot antipsychotic ...  > read more

Protein Marker For Schizophrenia Risk (July 10, 2008) — A protein found in immune cells may be a reliable marker for schizophrenia risk, report researchers in a new proteomics study. Schizophrenia is a severe and complex psychiatric illness that affects ...  > read more

Search ScienceDaily

Gene Chip for Personalized Meds